Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells

Biochemical and Biophysical Research Communications
Wei-Jun LiuJian Ding

Abstract

The telomere and telomerase have been suggested as targets for anticancer drug discovery. However, the mechanisms by which conventional anticancer drugs affect these targets are currently unclear. The novel topoisomerase II inhibitor, salvicine, suppresses telomerase activity in leukemia HL-60 cells. To further determine whether this activity of salvicine is specific to the hematological tumor and distinct from those of other conventional anticancer agents, we studied its effects on telomere and telomerase in a solid lung carcinoma cell line, A549. Differences in telomerase inhibition and telomere erosion were observed between salvcine and other anticancer agents. All anticancer agents (except adriamycin) induced shortening of the telomere, which was identified independent of replication, but only salvicine inhibited telomerase activity in A549 cells under conditions of high concentration and short-term exposure. At the low concentration and long-term exposure mode, all the tested anticancer agents shortened the telomere and inhibited telomerase activity in the same cell line. Notably, salvicine inhibited telomerase activity more severely than the other agents examined. Moreover, the compound inhibited telomerase activity in A5...Continue Reading

References

Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A M BurgerD R Newell
Jan 22, 1998·Biochemical and Biophysical Research Communications·W C KuT C Wang
Oct 6, 1999·Bioorganic & Medicinal Chemistry Letters·J S ZhangS T Yuan
Oct 25, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M FoliniN Zaffaroni
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T R CresseyD R Newell
Sep 5, 2002·Microbiology and Molecular Biology Reviews : MMBR·Yu-Sheng CongJerry W Shay
May 22, 2003·Cancer Letters·Gabriele Saretzki
Jul 23, 2003·Trends in Pharmacological Sciences·Fred O Odago, Stanton L Gerson

❮ Previous
Next ❯

Citations

Feb 24, 2007·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Ming-Wei WangKaixian Chen
Feb 14, 2006·Critical Reviews in Oncology/hematology·Ken André OlaussenJean-Charles Soria
Dec 28, 2007·Cellular & Molecular Biology Letters·Kulthum Mohammed, Amal Shervington
Apr 28, 2016·Pharmacology & Therapeutics·Yinnan Chen, Yanmin Zhang
Apr 28, 2020·BioMed Research International·Hua-Zhong YingWen-Ying Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis